Indexing disease progression at study entry with individuals at-risk for Huntington disease

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 156, Issue 7, 2011, Pages 751-763

  Zhang, Ying ^a   Long, Jeffrey D ^b   Mills, James A ^b   Warner, John H ^c   Lu, Wenjing ^a   Paulsen, Jane S ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c CHDI MANAGEMENT CHDI FOUNDATION   (United States)

Author keywords

PREDICT HD study; Prodromal Huntington disease; Survival analysis

Indexed keywords

ADENINE; CYTOSINE; GUANINE;

ADULT; ARTICLE; BOOTSTRAPPING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; FEMALE; GENE MUTATION; GENETIC RISK; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL;

AGING; AREA UNDER CURVE; CONFIDENCE INTERVALS; DISEASE PROGRESSION; HUMANS; HUNTINGTON DISEASE; MODELS, STATISTICAL; REPRODUCIBILITY OF RESULTS; RISK FACTORS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 80052484592     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.31232     Document Type: Article

References (55)

1. Andresen JM, Gayan J, Cherny SS, Brocklebank D, Alkorta-Aranburu G, Addis EA, Cardon LR, Housman DE, Wexler NS. 2007a. Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds. J Med Genet 44(1): 44-50.
2. Andresen JM, Gayan J, Djousse L, Roberts S, Brocklebank D, Cherny SS, Cardon LR, Gusella JF, MacDonald ME, Myers RH, et al. 2007b. The relationship between CAG repeat length and age of onset differs for Huntington's disease patients with juvenile onset or adult onset. Ann Hum Genet 71(Pt 3): 295-301.
3. Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, Starr E, Squitieri F, Lin B, Kalchman MA, et al. 1993. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 4(4): 398-403.
4. Aylward EH, Nopoulos PC, Ross CA, Langbehn DR, Pierson RK, Mills JA, Johnson HJ, Magnotta VA, Juhl AR, Paulsen JS. 2010. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 82: 405-410.
5. Beglinger LJ, Paulsen JS, Watson DB, Wang C, Duff K, Langbehn DR, Moser DJ, Paulson HL, Aylward EH, Carlozzi NE, et al. 2008. Obsessive and compulsive symptoms in prediagnosed Huntington's disease. J Clin Psychiatry 69(11): 1758-1765.
6. Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S, Carlozzi NE, Duff K, Beglinger LJ, Paulsen JS, et al. 2009. Motor abnormalities in premanifest persons with Huntington's disease: The PREDICT-HD study. Mov Disord 24(12): 1763-1772.
7. Bleeker SE, Moll HA, Steyerberg EW, Donders ART, Derkson-Lubsen G, Grobbee DE, Moons KGM. 2003. External validation is necessary in prediction research: A clinical example. J Clin Epidemiol 56(9): 826-832.
8. Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR. 1997. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 60(5): 1202-1210.
9. Bruland O, Almqvist EW, Goldberg YP, Boman H, Hayden MR, Knappskog PM. 1999. Accurate determination of the number of CAG repeats in the Huntington disease gene using a sequence-specific internal DNA standard. Clin Genet 55(3): 198-202.
10. Burnham KP, Anderson DR. 2002. Model selection and multimodel inference: A practical information-theoretic approach. New York: Springer. xxvi, 488 p.
11. Campodonico JR, Codori AM, Brandt J. 1996. Neuropsychological stability over two years in asymptomatic carriers of the Huntington's disease mutation. J Neurol Neurosurg Psychiatry 61(6): 621-624.
12. Casella G, Berger RL. 2002. Statistical inference. Australia: Pacific Grove, CA/Thomson Learning. xxviii, 660 p.
13. Duff K, Paulsen J, Mills J, Beglinger LJ, Moser DJ, Smith MM, Langbehn D, Stout J, Queller S, Harrington DL. 2010a. Mild cognitive impairment in prediagnosed Huntington disease. Neurology 75(6): 500-507.
14. Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Wang C, Stout JC, Ross CA, Aylward E, Carlozzi NE, Queller S. 2010b. "Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: Evidence of early lack of awareness. J Neuropsychiatry Clin Neurosci 22(2): 196-207.
15. Efron B. 1986. How biased is the apparent error rate on a prediction rule? J Am Stat Assoc 81(394): 461-470.
16. Efron B, Tibshirani R. 1993. An introduction to the bootstrap. Monographs on statistics and applied probability. New York: Chapman & Hall. 456 p.
17. Grace J, Malloy P. 2001. Frontal Systems Behavior Scale (FrSBe): Professional manual. Lutz, FL: Psychological Assessment Resources. 109 p.
18. Gutiérrez C, MacDonald A. 2002. Huntington's Disease and Insurance I: A model of Huntington's disease. Edinburgh: Genetics and Insurance Research Centre (GIRC). 28 p.
19. Gutiérrez C, MacDonald A. 2004. Huntington's disease, critical illness insurance and life insurance. Scand Actuarial J 4: 279-311.
20. Harrell FE, Lee KL, Mark DB. 1996. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15(4): 361-387.
21. Heagerty PJ, Zheng Y. 2005. Survival model predictive accuracy and ROC curves. Biometrics 61(1): 92-105.
22. Heagerty PJ, packaging by Saha P. 2011. risksetROC: Riskset ROC curve estimation from censored survival data. R package version 1.0.3. .
23. Huntington Study Group. 1996. Unified Huntington's Disease Rating Scale: Reliability and consistency. Mov Disord 11(2): 136-142.
24. Klein J, Moeschberger M. 2003. Survival analysis. Techniques for censored and truncated data. New York: Springer-Verlag.
25. Kleinbaum DG, Klein M. 2005. Chapter 2: Kaplan-Meier survival curves and the log-rank test. Survival analysis: A self-learning text 2nd edition. New York, NY: Springer. p xv, 590 p.
26. Klöppel S, Chu C, Tan GC, Draganski B, Johnson H, Paulsen JS, Kienzle W, Tabrizi SJ, Ashburner J, Frackowiak RS, et al. 2009. Automatic detection of preclinical neurodegeneration: Presymptomatic Huntington disease. Neurology 72(5): 426-431.
27. Kremer B, Goldberg P, Andrew SE, Theilmann J, Telenius H, Zeisler J, Squitieri F, Lin B, Bassett A, Almqvist E, et al. 1994. A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl J Med 330(20): 1401-1406.
28. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. 2004. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 65(4): 267-277.
29. Langbehn DR, Hayden MR, Paulsen JS, Investigators P-H. 2010. CAG-repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches. Am J Med Genet Part B 153B: 397-408.
30. Langbehn DR, Paulsen JS. 2007. Predictors of diagnosis in Huntington disease. Neurology 68(20): 1710-1717.
31. Laupacis A, Sekar N, Stiell IG. 1997. Clinical prediction rules. A review and suggested modifications of methodological standards. JAMA 277(6): 488-494.
32. Lucotte G, Turpin JC, Riess O, Epplen JT, Siedlaczk I, Loirat F, Hazout S. 1995. Confidence intervals for predicted age of onset, given the size of (CAG)n repeat, in Huntington's disease. Hum Genet 95(2): 231-232.
33. Maat-Kievit A, Losekoot M, Zwinderman K, Vegter-van derVlis M, Belfroid R, Lopez F, Van Ommen GJ, Breuning M, Roos R. 2002. Predictability of age at onset in Huntington disease in the Dutch population. Medicine (Baltimore) 81(4): 251-259.
34. Miller ME, Langefeld CD, Tierney WM, Hui SL, McDonald CJ. 1993. Validation of probabilistic predictions. Med Decis Making 13(1): 49-58.
35. Nance MA, Mathias-Hagen V, Breningstall G, Wick MJ, McGlennen RC. 1999. Analysis of a very large trinucleotide repeat in a patient with juvenile Huntington's disease. Neurology 52(2): 392-394.
36. Nopoulos PC, Aylward EH, Ross CA, Johnson HJ, Magnotta VA, Juhl AR, Pierson RK, Mills J, Langbehn DR, Paulsen JS. 2010. Cerebral cortex structure in prodromal Huntington disease. Neurobiol Dis 40(3): 544-554.
37. Nopoulos PC, Aylward EH, Ross CA, Mills JA, Langbehn DR, Johnson HJ, Magnotta VA, Pierson RK, Beglinger LJ, Nance MA, et al. 2011. Smaller intracranial volume in prodromal Huntington's disease: Evidence for abnormal neurodevelopment. Brain 134(Pt 1): 137-142.
38. Paulsen J. 2010. Early detection of Huntington's disease. Future Neurol 5(1): 85-104.
39. Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, Guttman M, Nance M, Kieburtz K, Oakes D, et al. 2006. Preparing for preventive clinical trials: The Predict-HD study. Arch Neurol 63(6): 883-890.
40. Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, et al. 2008. Detection of Huntington's disease decades before diagnosis: The Predict-HD study. J Neurol Neurosurg Psychiatry 79(8): 874-880.
41. Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, Magnotta VA, Juhl A, Pierson RK, Mills J, Langbehn D, et al. 2010a. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull 82(3-4): 201-207.
42. Paulsen JS, Wang C, Duff K, Barker R, Nance M, Beglinger L, Moser D, Williams JK, Simpson S, Langbehn D, et al. 2010b. Challenges assessing clinical endpoints in early Huntington disease. Mov Disord 25(15): 2595-2603.
43. Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. 1997. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 41(5): 689-692.
44. R Development Core Team. 2010. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. ISBN 3-900051-07-0.
45. Rowe KC, Paulsen JS, Langbehn DR, Duff K, Beglinger LJ, Wang C, O'Rourke JJ, Stout JC, Moser DJ. 2010. Self-paced timing detects and tracks change in prodromal Huntington disease. Neuropsychology 24(4): 435-442.
46. Rubinsztein DC, Leggo J, Chiano M, Dodge A, Norbury G, Rosser E, Craufurd D. 1997. Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease. Proc Natl Acad Sci USA 94(8): 3872-3876.
47. Rubinsztein DC, Leggo J, Coles R, Almqvist E, Biancalana V, Cassiman JJ, Chotai K, Connarty M, Crauford D, Curtis A, et al. 1996. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet 59(1): 16-22.
48. Squitieri F, Sabbadini G, Mandich P, Gellera C, Di Maria E, Bellone E, Castellotti B, Nargi E, de Grazia U, Frontali M, et al. 2000. Family and molecular data for a fine analysis of age at onset in Huntington disease. Am J Med Genet 95(4): 366-373.
49. Stine OC, Pleasant N, Franz ML, Abbott MH, Folstein SE, Ross CA. 1993. Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. Hum Mol Genet 2(10): 1547-1549.
50. Stout JC, Paulsen JS, Queller S, Solomon AC, Whitlock KB, Campbell JC, Carlozzi N, Duff K, Beglinger LJ, Langbehn DR, et al. 2011. Neurocognitive signs in prodromal Huntington disease. Neuropsychology 25(1): 1-14.
51. Therneau T, original Splus->R, port by, Thomas Lumley. 2009. survival: Survival analysis, including penalised likelihood. R package version 2.35-8.
52. Watson D, Wu KD. 2005. Development and validation of the schedule of compulsions, obsessions, and pathological impulses (SCOPI). Assessment 12(1): 50-65.
53. Wolkewitz M, Allignol A, Schumacher M, Beyersmann J. 2010. Two pitfalls in survival analyses of time-dependent exposure: A case study in a cohort of Oscar nominees. Am Stat 64(3): 205-211.
54. Zelen M, Feinleib M. 1969. On the theory of screening for chronic diseases. Biometrika 56(3): 601-614.
55. Zelen M. 2005. Forward and backward recurrence times and length biased sampling: Age specific models. Lifetime Data Anal 10(4): 325-334.